Bruton's Tyrosine Kinase (BTK) Inhibitors: Competitive Landscape, Pipeline and Market Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 30+ products along with 25+ companies involved. Acerta Pharma and BeiGene are developing therapeutic drugs in the higher phase and Acerta Pharma has been granted both Orphan and Breakthrough Therapy Designation from FDA.

Products covered by Phase

  • Filed, Phase III, Phase II and Phase I
  • IND and Pre-clinical

Overview of pipeline development activities for Bruton's Tyrosine Kinase (BTK) Inhibitors

  • Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
  • Therapeutic segmentation of products for Bruton's Tyrosine Kinase (BTK) Inhibitors
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

Scope

  • The report provides competitive pipeline landscape of Bruton's Tyrosine Kinase (BTK) Inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Bruton's Tyrosine Kinase (BTK) Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Bruton's Tyrosine Kinase (BTK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Bruton's Tyrosine Kinase (BTK) Inhibitors and also provides company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till pre-clinical stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Companies Mentioned

  • AbbVie
  • ACEA Biosciences
  • Acerta Pharma
  • Aptose Biosciences
  • ArQule
  • BeiGene
  • Biogen
  • Bristol- Myers Squibb
  • Carna Biosciences
  • Celgene Corporation
  • Eternity Bioscience
  • Gilead Sciences
  • Hanmi Pharmaceutical
  • KBP Biosciences
  • Loxo Oncology
  • LSK BioPharma
  • Merck
  • Ono Pharmaceutical
  • Pharmacyclics
  • Principia Biopharma
  • Roche
  • Sunesis
  • Takeda
  • Tolero
  • X-Rx
  • Zhejiang DTRM Biopharma

For more information about this report visit https://www.researchandmarkets.com/research/4gsg34/brutons_tyrosine?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs , Enzymes

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs , Enzymes